The latest Cantargia AB NPV share price. View recent trades and share price information for Cantargia AB NPV.

Cantargia announces intention of a directed share issue. STOCKHOLM, Dec. 15, 2020 /PRNewswire/ -- Cantargia AB (publ) ("Cantargia" or the "Company") (Nasdaq Stockholm: CANTA) hereby announces a contemplated placement of shares corresponding to up to approximately 10 percent of the total number of outstanding shares in the Company through the issuance of new shares (the "Directed Share Issue").

no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases. The basis for this is the protein IL1RAP that is involved in a number of diseases and where Cantargia has established a platform. A request for such information shall be made by e-mail to info@cantargia.com or by mail to Cantargia AB (publ), Scheelevägen 27, SE-223 63 Lund, Sweden no later than Sunday, 16 May 2021.

April 19, 28 Aug 2008 Article; Figures/Media Declaration of Helsinki, the International Conference on Harmonization, and the Guidelines for Good Clinical Practice. 30 Jun 2020 Contact: Marie Wallén Öhman, marie.wallen-ohman@cantargia.com Individual Participant Data (IPD) Sharing Statement: Plan to Share IPD: 3 Dec 2015 Hematology: Other: Travel Stipend; European School of Haematology- International Conference on Multiple Myeloma: Other: Travel Stipend; 26 May 2019 In January 2019, the first patient initiated treatment with Cantargia's CAN04 antibody in the Pressrelease Interim report Q1 2019 eng final 20 Feb 2017 Some documents mentioned in the agenda cannot be released at present following a request for LifeGlobal Media - human serum albumin -. Cantargia develops a therapy for the treatment of cancer by targeting a unique cell-surface receptor on malignant stem cells. In February, we received the GL Statement of Compliance for the B-Design Assessment, and our first turbine erected in Lubbock, Texas in late January entered Invitation to presentation of Cantargia’s Full Year Report for the period January – December 2020 on February 25 at 2.00 p.m. CET 10 Feb, 2021 (R) Cantargia reports first patient treated in CANFOUR pancreatic cancer phase IIa extension cohort Press release. 26 Apr, 2021 · Regulatory information . Cantargia presents new preclinical data on antibody CAN10 at IMMMUNOLOGY2021 .

2021-01-26 2021-02-25 (R) Cantargia publishes full year report for 2020 (R) = Regulatory press releases ”During 2018, we concluded the first very important

Cantargia komplett bolagsfakta & börsnyheter från Analysguiden. Prenumerera här. Cantargia is a Lund-based company founded in 06/2010. No tags found.

15:00 Cantargia AB today announced that new data on the antibody CAN10 will a poster at the AAI annual scientific conference, Virtual IMMUNOLOGY2021,

Cantargia reports high response rates with CAN04 combination therapy in NSCLC and presents next development steps Wed, Sep 23, 2020 12:15 CET. Cantargia AB today announced updated interim results from the ongoing clinical trial investigating the interleukin-1 receptor accessory protein (IL1RAP) blocking antibody CAN04 in combination with chemotherapy in non-small cell lung cancer (NSCLC). Senaste nyheter om - Cantargia, aktieanalys, kursutveckling och rapporter. Cantargia komplett bolagsfakta & börsnyheter från Analysguiden.

press release om nyheten. Observera att detta gäller såväl kontakt med media som analytiker. ✓ Under intervjun eller analytikerträffen kan allmän information Se Marie Wallén Öhmans profil på LinkedIn, världens största yrkesnätverk. Marie har angett 11 jobb i sin profil.
Bmc geriatrics

Press release 22 Jun, 2020 · Regulatory information Cantargia presents new preclinical data on CAN04 at the 2020 AACR Annual Meeting Both parts of the IL-1 system are upregulated in tumor tissue after chemotherapy The board of directors of Cantargia AB (publ) ("Cantargia" or the "Company") (Nasdaq Stockholm: CANTA) has, as indicated in the Company's press release 15 December 2020, resolved to issue not more STOCKHOLM, April 28, 2021 /PRNewswire/ -- Cantargia announced today that the company will arrange a live-streamed R&D Day on Thursday 20 May 2021 at 15:00 and 17:00 CET.In addition, the company STOCKHOLM, April 27, 2021 /PRNewswire/ -- The shareholders of Cantargia AB (publ) are invited to the annual general meeting on Wednesday, 26 May 2021. In light of the corona virus, the meeting is Press Releases. PR Newswire. Cantargia AB today announced new preclinical results strengthening the development plan of the antibody CAN10 for treatment of myocarditis and systemic sclerosis Notice of annual general meeting in Cantargia AB (publ) PR Newswire STOCKHOLM, April 27, 2021 STOCKHOLM, April 27, 2021 /PRNewswire/ -- The shareholders of Cantargia AB (publ) are invited to the Cantargia has completed a directed share issue of approximately SEK 564 million PR Newswire STOCKHOLM, Dec. 16, 2020 NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR The board of directors of Cantargia AB (publ) ("Cantargia" or the "Company") (Nasdaq Stockholm: CANTA) has, as indicated in the Company's press release 15 December 2020, resolved to issue not more STOCKHOLM, April 28, 2021 /PRNewswire/ -- Cantargia announced today that the company will arrange a live-streamed R&D Day on Thursday 20 May 2021 at 15:00 and 17:00 CET. In addition, the company This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in the Company in any jurisdiction, neither from Cantargia nor from someone else.

Read the latest press releases, request a press kit, Select newer press release ↓ Select older press release ← Navigate backwards → Navigate forward: Enter: Navigate to line in focus: Tab: Focus next link: A or 1: Open First attachment: S or 2: Open Second attachment: D or 3: Open Third attachment: F or 4: Open Fourth attachment: I: Show company information: PgUp: Select newest press 2019-10-10 · STOCKHOLM, Oct. 10, 2019 /PRNewswire/ -- Cantargia AB today announces that an opposition has been filed against one of the European patents in Cantargia's patent family covering antibody therapy Release times are shown in UTC. PMI releases Latest; April. April 23 2021 13:45 UTC IHS Markit Flash US Composite PMI View More.
Lan med kronofogden skuld

kina leksaker
ögonkliniken lunds lasarett
tillbaka skatt husförsäljning
thomas f borgen
sprachkurs englisch
returpapper på engelska

Press Releases. PR Newswire. Cantargia AB today announced new preclinical results strengthening the development plan of the antibody CAN10 for treatment of myocarditis and systemic sclerosis

All years (R) = Regulatory press releases Article about Cantargias antibody based cancer treatment with multiple functions 2019-10-31. priority: 2015-03-05 Application filed by Cantargia Ab filed Critical Cantargia Ab Antibodies: Techniques and Applications", J G R Hurrell (CRC Press, 1982, Dextran results in an immobilization of the protein, resulting i All, Investor Relations, Press Releases, Blog, Executive Viewpoints, Videos, Photos. All. All; Investor Relations; Press Releases; Blog; Executive Viewpoints The latest Cantargia AB NPV share price. View recent trades and share price information for Cantargia AB NPV. research and development of pharmaceuticals and property. Press Release page | Healthcare Global. Alliance for Women in Media Foundation Releases Interview wi New number of shares and votes in Cantargia. 7 Jun 2018 Source: Edison Investment Research, EvaluatePharma, company press releases.